SCHEMBL2297181

SCHEMBL2297181

c1ccc2c(c1)ncc1cocc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 3/20 0.61
KDM4E B2RXH2 2/20 0.61
TOP2A P11388 1/20 0.44
ADORA3 P0DMS8 1/20 0.40
PDPK1 O15530 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.38
KMT2A Q03164 1/20 0.37
ERN1 O75460 1/20 0.37
MAPT P10636 1/20 0.37
DUSP10 Q9Y6W6 1/20 0.35
PDE10A Q9Y233 1/20 0.35
NCF1 P14598 1/20 0.35
PI4KA P42356 1/20 0.35
PI4K2B Q8TCG2 1/20 0.35
PI4K2A Q9BTU6 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthridine SCHEMBL30914262 0.76 GPR3 (1.00) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL9106884 0.76 GPR3 (1.00) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL8666 0.76 GPR3 (1.00) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL30823553 0.76 GPR3 (1.00) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL23003530 0.74 GPR3 (0.95) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL3702845 0.74 GPR3 (0.95) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL460289 0.74 GPR3 (0.95) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL2422346 0.74 GPR3 (0.95) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL8505090 0.74 GPR3 (0.95) GPR3KDM4ETOP2AADORA3PDPK1
Phenanthridine SCHEMBL2421052 0.74 GPR3 (0.95) GPR3KDM4ETOP2AADORA3PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150583-B2 Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
EP-2760868-A1 FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION Boehringer Ingelheim International GmbH (DE) 2014-08-06 EP disclosed
EP-2675811-A1 TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION Boehringer Ingelheim International GmbH (DE) 2013-12-25 EP disclosed
US-20130210850-A1 Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-15 US disclosed
WO-2013024130-A1 FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-21 WO disclosed
EP-2536733-A1 TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION Boehringer Ingelheim International GmbH (DE) 2012-12-26 EP disclosed
WO-2012110599-A1 TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 WO disclosed
WO-2011101424-A1 TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210850-A1 Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation CETP, MTTP, NPC1L1 GPR3 1547/4885KDM4E 2212/4885TOP2A 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.